Treatment with anti-VLA-4 and LFA-1 monoclonal antibodies prolongs intraportal rat islet allograft survival.
Yang
H
H
Department of Pathology, Izaak Walton Killam Children's Hospital, Halifax, Nova Scotia, Canada.
Issekutz
T B
TB
Wright
J R
JR
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000473:pathology / Q000628:therapy*; D006085:Graft Survival / Q000502:physiology*; D007165:Immunosuppression Therapy / Q000379:methods; D016381:Islets of Langerhans Transplantation / Q000276:immunology / Q000473:pathology / Q000502:physiology*; D016169:Lymphocyte Function-Associated Antigen-1 / Q000276:immunology*; D008297:Male; D011168:Portal System; D051381:Rats; D011917:Rats, Inbred Lew; D011920:Rats, Inbred WF; D016029:Receptors, Very Late Antigen / Q000276:immunology*; D016042:Transplantation, Heterotopic; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D016169:Lymphocyte Function-Associated Antigen-1; D016029:Receptors, Very Late Antigen